Company Overview - Sunflower Health Technology Co., Ltd. is located in Shaoxing, Zhejiang Province, established on March 21, 2005, and listed on August 27, 2010. The company focuses on the pharmaceutical sector, primarily engaged in the research, production, and sales of anti-infection, cardiovascular, and digestive system drugs [1][2]. Financial Performance - For the period from January to September 2025, Sunflower achieved operating revenue of 200 million yuan, a year-on-year decrease of 12.09%. The net profit attributable to the parent company was 1.31 million yuan, down 53.10% year-on-year [2]. - The company has cumulatively distributed 204 million yuan in dividends since its A-share listing, with no dividends distributed in the last three years [3]. Stock Performance - As of November 14, Sunflower's stock price decreased by 2.09%, trading at 7.50 yuan per share, with a total market capitalization of 9.654 billion yuan. The stock has increased by 131.48% year-to-date but has seen a decline of 5.06% over the last five trading days and 11.66% over the last 20 days [1]. - The stock has appeared on the "Dragon and Tiger List" five times this year, with the most recent appearance on October 27, where it recorded a net purchase of 412 million yuan [1]. Shareholder Information - As of September 30, the number of shareholders for Sunflower was 133,000, an increase of 112.98% from the previous period. The average number of circulating shares per shareholder was 9,676, a decrease of 53.05% [2]. Industry Classification - Sunflower belongs to the pharmaceutical and biological industry, specifically in the chemical pharmaceutical and chemical preparation sectors. It is associated with concepts such as raw materials, annual strength, Helicobacter pylori concept, small-cap stocks, and hypertension prevention [2].

Core Viewpoint - The stock of Guangzhou Kingmed Diagnostics Group Co., Ltd. has shown a positive trend, with a year-to-date increase of 15.38% and a recent uptick in trading activity, indicating potential investor interest and market confidence [1][2]. Company Overview - Guangzhou Kingmed Diagnostics Group Co., Ltd. was established on May 26, 2006, and went public on September 8, 2017. The company provides a wide range of diagnostic services to over 23,000 medical institutions across China, covering nearly 80 types of testing technologies and approximately 3,200 testing items [2]. - The company's revenue composition includes 91.20% from medical diagnostic services, 6.45% from sales of diagnostics, and smaller contributions from other services [2]. Financial Performance - For the period from January to September 2025, Kingmed Diagnostics reported a revenue of 4.538 billion yuan, reflecting a year-on-year decrease of 19.23%. The net profit attributable to shareholders was -796.095 million yuan, a significant decline of 184.84% compared to the previous year [2]. - The company has distributed a total of 2.545 billion yuan in dividends since its A-share listing, with 1.647 billion yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Kingmed Diagnostics was 41,700, a decrease of 1.60% from the previous period. The average number of circulating shares per shareholder increased by 1.62% to 11,042 shares [2]. - The second-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 35.5057 million shares, which is a reduction of 2.8676 million shares from the previous period [3].

Core Viewpoint - Yiling Pharmaceutical's stock has shown significant growth this year, with a year-to-date increase of 30.17% and a recent surge of 16.72% over the past five trading days [1] Financial Performance - For the period from January to September 2025, Yiling Pharmaceutical reported a revenue of 5.868 billion yuan, a year-on-year decrease of 7.82%, while the net profit attributable to shareholders was 1 billion yuan, reflecting a year-on-year increase of 80.33% [2] - The company has cumulatively distributed 4.455 billion yuan in dividends since its A-share listing, with 1.838 billion yuan distributed over the past three years [3] Stock Market Activity - As of November 13, Yiling Pharmaceutical's stock price reached 20.45 yuan per share, with a trading volume of 1.068 billion yuan and a turnover rate of 3.91% [1] - The company has appeared on the "Dragon and Tiger List" once this year, with a net purchase of 640.503 million yuan on January 6 [1] Shareholder Structure - As of September 30, 2025, Yiling Pharmaceutical had 152,700 shareholders, a decrease of 10.22% from the previous period, with an average of 9,013 circulating shares per shareholder, an increase of 11.38% [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited as the third-largest shareholder, increasing its holdings by 8.1119 million shares [3]

Core Insights - Boji Pharmaceutical's stock price increased by 2.19% on November 13, reaching 10.74 CNY per share, with a total market capitalization of 4.143 billion CNY [1] - The company has seen a year-to-date stock price increase of 23.19%, with a 7.51% rise over the last five trading days [1] Financial Performance - For the period from January to September 2025, Boji Pharmaceutical reported a revenue of 584 million CNY, representing a year-on-year growth of 5.06% [2] - The net profit attributable to shareholders was 21.9139 million CNY, which reflects a significant decrease of 49.36% compared to the previous year [2] Business Overview - Boji Pharmaceutical specializes in providing preclinical research services, clinical research services, technology transfer services, and consulting services related to new drug development [1] - The revenue composition of the company includes 80.18% from clinical research services, 11.31% from preclinical research services, 6.50% from other consulting services, and 2.02% from supplementary services [1] Shareholder Information - As of September 30, the number of shareholders for Boji Pharmaceutical was 29,600, an increase of 18.91% from the previous period [2] - The average number of circulating shares per shareholder decreased by 15.21% to 9,497 shares [2] Dividend Information - Since its A-share listing, Boji Pharmaceutical has distributed a total of 27.7583 million CNY in dividends, with 12.0783 million CNY distributed over the last three years [3]

11月12日，东方生物盘中上涨2.10%，截至10:24，报27.75元/股，成交5771.05万元，换手率1.04%，总 市值55.94亿元。 资金流向方面，主力资金净流入581.66万元，特大单买入184.64万元，占比3.20%，卖出221.20万元，占 比3.83%；大单买入1529.76万元，占比26.51%，卖出911.54万元，占比15.80%。 东方生物今年以来股价跌5.39%，近5个交易日涨5.35%，近20日涨8.99%，近60日跌4.24%。 资料显示，浙江东方基因生物制品股份有限公司位于浙江省湖州市安吉县递铺街道阳光大道东段3787 号，成立日期2005年12月1日，上市日期2020年2月5日，公司主营业务涉及体外诊断产品研发、生产与 销售。主营业务收入构成为：体外诊断试剂97.99%，其他(补充)2.01%。 东方生物所属申万行业为：医药生物-医疗器械-体外诊断。所属概念板块包括：基因测序、小盘、抗流 感、幽门螺杆概念、禽流感药物等。 截至9月30日，东方生物股东户数1.33万，较上期减少3.93%；人均流通股15170股，较上期增加4.09%。 2025年1月-9月，东方生物实现营 ...

Core Viewpoint - Huason Pharmaceutical's stock has shown a significant increase this year, with a year-to-date rise of 31.24%, indicating strong market interest and performance [2]. Group 1: Stock Performance - As of November 12, Huason Pharmaceutical's stock price rose by 2.05% to 16.95 CNY per share, with a market capitalization of 7.078 billion CNY [1]. - The stock has experienced a 3.99% increase over the last five trading days and a 1.13% increase over the last 20 days, while it has decreased by 5.65% over the last 60 days [2]. Group 2: Financial Performance - For the period from January to September 2025, Huason Pharmaceutical reported a revenue of 626 million CNY, reflecting a year-on-year growth of 1.90%, while the net profit attributable to shareholders was 72.4556 million CNY, a decrease of 2.84% year-on-year [3]. - The company has distributed a total of 192 million CNY in dividends since its A-share listing, with 100 million CNY distributed in the last three years [4]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders increased to 33,100, with an average of 9,063 circulating shares per person, a slight decrease of 0.83% [3]. - The fifth largest circulating shareholder, Hong Kong Central Clearing Limited, reduced its holdings by 1.4123 million shares to 2.6207 million shares [4]. Group 4: Business Overview - Huason Pharmaceutical, established on November 4, 1996, operates in the pharmaceutical industry, focusing on research, production, and sales, with a revenue composition that includes 34.24% from ENT medications, 23.16% from digestive system medications, and 18.37% from psychiatric medications [2]. - The company is categorized under the pharmaceutical and biological industry, specifically in traditional Chinese medicine and generic drugs [2].

Company Overview - Zhejiang Anglikang Pharmaceutical Co., Ltd. was established on December 30, 2001, and listed on October 23, 2018. The company is engaged in the research, production, and sales of chemical raw materials and preparations [1] - The main business revenue composition includes preparations (43.46%), raw materials (39.82%), specialty intermediates (12.44%), others (3.72%), and pharmaceutical excipients (0.56%) [1] Stock Performance - As of November 12, Anglikang's stock price increased by 2.02%, reaching 43.50 CNY per share, with a total market capitalization of 8.775 billion CNY [1] - Year-to-date, Anglikang's stock price has risen by 233.13%, with an 8.42% increase over the last five trading days and a 5.58% increase over the last 20 days, while it has decreased by 17.97% over the last 60 days [1] Financial Performance - For the period from January to September 2025, Anglikang reported a revenue of 1.055 billion CNY, a year-on-year decrease of 5.92%, while the net profit attributable to shareholders was 77.6899 million CNY, reflecting a year-on-year increase of 55.59% [2] - The company has distributed a total of 341 million CNY in dividends since its A-share listing, with 108 million CNY distributed over the past three years [3] Shareholder Information - As of September 30, 2025, Anglikang had 28,500 shareholders, an increase of 54.58% from the previous period, with an average of 6,493 circulating shares per shareholder, a decrease of 35.31% [2] - Notable institutional shareholders include Guangfa Medical Healthcare Stock A, which holds 3.3384 million shares, and several new entrants among the top ten circulating shareholders [3]

Core Viewpoint - Kanghui Co., Ltd. has shown a significant stock price increase of 64.07% year-to-date, indicating strong market interest and potential growth in the pharmaceutical sector [2]. Financial Performance - As of September 30, Kanghui Co., Ltd. reported a revenue of 356 million yuan, a year-on-year decrease of 11.97%, and a net profit attributable to shareholders of -133 million yuan, reflecting a substantial decline of 246.07% [2]. - The company has cumulatively distributed 54.23 million yuan in dividends since its A-share listing, with no dividends paid in the last three years [3]. Stock Market Activity - The stock price of Kanghui Co., Ltd. rose by 2.04% on November 11, reaching 23.56 yuan per share, with a trading volume of 23.57 million yuan and a turnover rate of 1.01% [1]. - The stock has appeared on the "Dragon and Tiger List" five times this year, with the most recent instance on June 16, where it recorded a net purchase of 7.7 million yuan [2]. Shareholder Information - As of September 30, the number of shareholders for Kanghui Co., Ltd. was 9,458, a decrease of 21.15% from the previous period, while the average circulating shares per person increased by 26.82% to 10,560 shares [2]. Business Overview - Kanghui Co., Ltd., established on December 24, 2009, and listed on April 21, 2017, is primarily engaged in the research, development, production, and sales of traditional Chinese medicine, with its main business revenue composition being 60.68% from pharmaceutical manufacturing and 36.79% from pharmaceutical distribution [2]. - The company operates within the pharmaceutical and biotechnology sector, specifically in the traditional Chinese medicine sub-sector [2].

Core Viewpoint - Oriental Bio's stock price has shown fluctuations, with a recent increase of 2.05% and a year-to-date decline of 6.75%, indicating potential volatility in the market [1] Financial Performance - For the period from January to September 2025, Oriental Bio reported a revenue of 672 million yuan, reflecting a year-on-year growth of 2.16% [2] - The company experienced a net profit attributable to shareholders of -213 million yuan, which is an improvement of 18.89% compared to the previous period [2] Shareholder Information - As of September 30, 2025, the number of shareholders for Oriental Bio was 13,300, a decrease of 3.93% from the previous period [2] - The average number of circulating shares per shareholder increased by 4.09% to 15,170 shares [2] Dividend Distribution - Since its A-share listing, Oriental Bio has distributed a total of 1.607 billion yuan in dividends, with 336 million yuan distributed over the past three years [3] Institutional Holdings - As of September 30, 2025, the fourth largest circulating shareholder is Rongtong Health Industry Flexible Allocation Mixed A/B, holding 2.8 million shares, a decrease of 1.7001 million shares from the previous period [3] - Hong Kong Central Clearing Limited is the sixth largest shareholder, increasing its holdings by 139,400 shares to 1.4675 million shares [3] - The Southern Science and Technology Innovation Board 3-Year Open Mixed Fund maintained its holding of 780,900 shares, while the Medical Device ETF entered as a new shareholder with 757,900 shares [3]

Core Insights - The stock price of Anglikon increased by 2.07% on November 11, reaching 42.33 CNY per share, with a total market capitalization of 8.539 billion CNY [1] - Year-to-date, Anglikon’s stock has risen by 224.17%, with a recent 3.67% increase over the last five trading days [1] - For the first nine months of 2025, Anglikon reported a revenue of 1.055 billion CNY, a year-on-year decrease of 5.92%, while net profit attributable to shareholders increased by 55.59% to 77.6899 million CNY [2] Financial Performance - Anglikon has been listed on the stock market since October 23, 2018, and has a primary business focus on the research, production, and sales of chemical raw materials and formulations [1] - The revenue composition of Anglikon includes 43.46% from formulations, 39.82% from raw materials, 12.44% from specialty intermediates, 3.72% from others, and 0.56% from pharmaceutical excipients [1] - Cumulative cash dividends since the A-share listing amount to 341 million CNY, with 108 million CNY distributed over the past three years [3] Shareholder Structure - As of September 30, 2025, Anglikon had 28,500 shareholders, an increase of 54.58% from the previous period, with an average of 6,493 circulating shares per shareholder, a decrease of 35.31% [2] - Notable institutional shareholders include Guangfa Medical Healthcare Stock A, which increased its holdings by 95,050 shares, and new entrants such as Huatai-PineBridge Innovation Medical Mixed A [3]